Do the new PCPT findings make you less likely to recommend finasteride for PCa?

Share this article:

After 18 months of follow-up of patients in the Prostate Cancer Prevention Trial (PCPT), Ian M. Thompson, Jr. MD, and colleagues found that finasteride decreased the risk of prostate cancer (PCa) by about a one third, but it had no effect on overall survival or survival after the diagnosis of PCa, according to a report in the New England Journal of Medicine (2013;369:603-610). 

In an editorial accompanying the report, Michael LeFevre, MD, wrote that the safest conclusion one can draw about the use of finasteride for PCa prevention “is that it has no short- or long-term effect on all-cause mortality, so we cannot recommend its use to prolong life.” 

Renal & Urology News invites urologists to answer the following online poll question.


Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

Has the proportion of your patients undergoing prostate brachytherapy been declining?

Has the proportion of your patients undergoing prostate ...

Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.

Are statins a valid approach for preventing contrast-induced nephropathy (CIN)?

Are statins a valid approach for preventing contrast-induced ...

Patients treated with statins have a significant 55% decreased odds of contrast-induced nephropathy.

Are you surprised that targeted therapeutics for metastatic renal cell carcinoma (RCC) have not improved survival?

Are you surprised that targeted therapeutics for metastatic ...

A study found that targeted therapeutic agents for treating metastatic RCC has not led to an improvement in survival rates.